Plain-English translation of NCT07266545 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This research study is testing a medication called for people with depression—both unipolar depression (depression alone) and bipolar depression (depression as part of bipolar disorder). Researchers want to understand how changes in your genetic material (RNA) can predict whether the medication will help you feel better. If the medication doesn't fully work after 8 weeks, you'll have the option to continue in a second phase where another treatment may be added.
Depression affects millions of people, but not everyone responds the same way to the same medication. This study aims to discover a biological marker—a sign in your blood—that could help doctors predict in advance which patients will benefit most from this treatment, leading to faster relief and better outcomes.
You likely qualify if…
You likely don't qualify if…
You will take the medication starting at 10 mg per day, increasing to 20 mg per day after one week, for 8 weeks. During this time, you'll have clinic visits where your depression symptoms will be checked using standard rating scales, and blood samples will be collected to measure changes in your RNA. If your symptoms improve significantly, your participation in the main study ends. If they don't improve enough, you'll be offered a second 8-week phase where another treatment may be added to the medication to help you feel better.
AI-generated summary from trial data · Jul 2, 2026 · Not medical advice
United States
Phase
Post-approval monitoring
Sponsor
Mayo Clinic
Enrollment target
~120 participants
Started
February 2026
Primary completion
December 2028
Age range
18 Years – 65 Years
Last updated on clinicaltrials.gov in June 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Scott E. Feeder
Mayo Clinic
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.